Register a trial

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06976216




Registration number
NCT06976216
Ethics application status
Date submitted
9/05/2025
Date registered
16/05/2025

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)
Secondary ID [1] 0 0
2025-520746-30
Secondary ID [2] 0 0
CN012-0051
Universal Trial Number (UTN)
Trial acronym
MINDSET 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - KarXT
Treatment: Drugs - KarX-EC
Other interventions - Placebo

Active comparator: KarXT + KarX-EC -

Placebo comparator: Placebo -


Treatment: Drugs: KarXT
Specified dose on specified days

Treatment: Drugs: KarX-EC
Specified dose on specified days

Other interventions: Placebo
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)
Timepoint [1] 0 0
At week 24
Primary outcome [2] 0 0
Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+)
Timepoint [2] 0 0
At week 24
Secondary outcome [1] 0 0
Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL)
Timepoint [1] 0 0
At week 24
Secondary outcome [2] 0 0
Change from baseline in neuro psychiatric inventory (NPI) total score
Timepoint [2] 0 0
At week 24
Secondary outcome [3] 0 0
Number of participants with adverse events (AEs)
Timepoint [3] 0 0
At week 24
Secondary outcome [4] 0 0
Number of participants with serious adverse events (SAEs)
Timepoint [4] 0 0
At week 24
Secondary outcome [5] 0 0
Number of participants with adverse event of special interest (AESIs)
Timepoint [5] 0 0
At week 24
Secondary outcome [6] 0 0
Number of participants with AEs leading to study intervention discontinuation
Timepoint [6] 0 0
At week 24
Secondary outcome [7] 0 0
Number of participants with AEs leading to study discontinuation
Timepoint [7] 0 0
At week 24
Secondary outcome [8] 0 0
Number of participants with AEs leading to death
Timepoint [8] 0 0
At week 24
Secondary outcome [9] 0 0
Number of participants with clinically significant changes in vital signs
Timepoint [9] 0 0
At week 24
Secondary outcome [10] 0 0
Number of participants with clinically significant changes in electrocardiogram (ECG) tests
Timepoint [10] 0 0
At week 24
Secondary outcome [11] 0 0
Number of participants with clinically significant changes in Columbia-Suicide Severity Rating Scale (C-SSRS) tests
Timepoint [11] 0 0
At week 24
Secondary outcome [12] 0 0
Number of participants with clinically significant changes in weight
Timepoint [12] 0 0
At week 24
Secondary outcome [13] 0 0
Number of participants with clinically significant changes in safety laboratory tests
Timepoint [13] 0 0
At week 24

Eligibility
Key inclusion criteria
Inclusion Criteria

* Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.
* Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.
* Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.
* Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.
Minimum age
60 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment.
* Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.
* Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.
* Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that could affect safety or interfere with study procedures.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
25/07/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
23/02/2029
Actual
Sample size
Target
586
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 0279 - Kogarah
Recruitment hospital [2] 0 0
Local Institution - 0245 - Macquarie Park
Recruitment hospital [3] 0 0
Local Institution - 0244 - Sydney
Recruitment hospital [4] 0 0
Local Institution - 0242 - Carlton
Recruitment hospital [5] 0 0
Local Institution - 0243 - Perth
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2113 - Macquarie Park
Recruitment postcode(s) [3] 0 0
2010 - Sydney
Recruitment postcode(s) [4] 0 0
3053 - Carlton
Recruitment postcode(s) [5] 0 0
6005 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Ciudad Autonoma De Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Córdoba
Country [21] 0 0
Brazil
State/province [21] 0 0
Distrito Federal
Country [22] 0 0
Brazil
State/province [22] 0 0
Paraná
Country [23] 0 0
Brazil
State/province [23] 0 0
Sergipe
Country [24] 0 0
Brazil
State/province [24] 0 0
São Paulo
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Nova Scotia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Chile
State/province [29] 0 0
AN
Country [30] 0 0
Chile
State/province [30] 0 0
Región Metropolitana De Santiago
Country [31] 0 0
Croatia
State/province [31] 0 0
Grad Zagreb
Country [32] 0 0
Croatia
State/province [32] 0 0
Osijek
Country [33] 0 0
Croatia
State/province [33] 0 0
Rijeka
Country [34] 0 0
Croatia
State/province [34] 0 0
Zagreb
Country [35] 0 0
Czechia
State/province [35] 0 0
Brno-mesto
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomoucký Kraj
Country [37] 0 0
Czechia
State/province [37] 0 0
Plzen-mesto
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 6
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha 8
Country [40] 0 0
Czechia
State/province [40] 0 0
Rychnov nad Knežnou
Country [41] 0 0
Germany
State/province [41] 0 0
Bayern
Country [42] 0 0
Germany
State/province [42] 0 0
Niedersachsen
Country [43] 0 0
Germany
State/province [43] 0 0
Nordrhein-Westfalen
Country [44] 0 0
Germany
State/province [44] 0 0
Rheinland-Pfalz
Country [45] 0 0
Germany
State/province [45] 0 0
Berlin
Country [46] 0 0
Germany
State/province [46] 0 0
Bremen
Country [47] 0 0
Germany
State/province [47] 0 0
Hamburg
Country [48] 0 0
Greece
State/province [48] 0 0
Attikí
Country [49] 0 0
Greece
State/province [49] 0 0
Thessaloníki
Country [50] 0 0
Greece
State/province [50] 0 0
Thessalía
Country [51] 0 0
Greece
State/province [51] 0 0
Alexandroupolis
Country [52] 0 0
India
State/province [52] 0 0
Karnataka
Country [53] 0 0
India
State/province [53] 0 0
Telangana
Country [54] 0 0
India
State/province [54] 0 0
Uttar Pradesh
Country [55] 0 0
India
State/province [55] 0 0
West Bengal
Country [56] 0 0
Italy
State/province [56] 0 0
Lombardia
Country [57] 0 0
Italy
State/province [57] 0 0
Brescia
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Kwangju-Kwangyokshi
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Kyonggi-do
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul-teukbyeolsi [Seoul]
Country [61] 0 0
Poland
State/province [61] 0 0
Kujawsko-pomorskie
Country [62] 0 0
Poland
State/province [62] 0 0
Podlaskie
Country [63] 0 0
Poland
State/province [63] 0 0
Pomorskie
Country [64] 0 0
Poland
State/province [64] 0 0
Wielkopolskie
Country [65] 0 0
Puerto Rico
State/province [65] 0 0
San Juan
Country [66] 0 0
Romania
State/province [66] 0 0
Bucure?ti
Country [67] 0 0
Romania
State/province [67] 0 0
Ia?i
Country [68] 0 0
Spain
State/province [68] 0 0
Andalucía
Country [69] 0 0
Spain
State/province [69] 0 0
Barcelona [Barcelona]
Country [70] 0 0
Spain
State/province [70] 0 0
Catalunya [Cataluña]
Country [71] 0 0
Spain
State/province [71] 0 0
Lleida [Lérida]
Country [72] 0 0
Spain
State/province [72] 0 0
Navarra
Country [73] 0 0
Spain
State/province [73] 0 0
Madrid

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
8559073286
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06976216